Genetic Factors and MicroRNAs in the Development of Gallbladder Cancer: The Prospective Clinical Targets-Reference-Cited by-同舟云学术

Genetic Factors and MicroRNAs in the Development of Gallbladder Cancer: The Prospective Clinical Targets

Published:2024-04 Issue:6 Volume:25 Page:375-387
ISSN:1389-4501
Container-title:Current Drug Targets
language:en
Short-container-title:CDT

Author:

Quraishi Roshni¹,Sanyal Somali¹,Dwivedi Medha¹,Moitra Monika¹,Dwivedi Manish¹²^ORCID

Affiliation:

1. Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow Campus, Gomtinagar Extension, Lucknow-226028, India

2. Research Cell, Amity University Uttar Pradesh, Lucknow Campus, Gomtinagar Extension, Lucknow-226028, India

Abstract

Abstract: Gallbladder cancer (GBC) is an uncommon condition in which malignant (cancer) cells are detected in gallbladder tissue. Cancer is often triggered when normal cells turn malignant and begin to spread. Cancer can also be caused by genetic anomalies that result in uncontrolled cell proliferation and tumor development. MicroRNAs (also known as miRNAs or miRs) are a group of small, endogenous, non-coding RNAs of 19-23 nucleotides in length, which play a key role in post-transcriptional gene regulation. These miRNAs serve as negative gene regulators by supervising target genes and regulating biological processes, including cell proliferation, migration, invasion, and apoptosis. Cancer development and progression relate to aberrant miRNA expression. This review demonstrated the implication of various genetic factors and microRNAs in developing and regulating GBC. This suggests the potential of genes and RNAs as the diagnostic, prognostic, and therapeutic targets in gallbladder cancer.

Funder

DST-INSPIRE Faculty Award

Publisher

Bentham Science Publishers Ltd.

Reference100 articles.

1. Hundal R.; Shaffer E.A.; Gallbladder cancer: Epidemiology and outcome. Clin Epidemiol 2014,6,99-109

2. Ueno H.; Okusaka T.; Ikeda M.; Takezako Y.; Morizane C.; Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 2004,91(10),1769-1774

3. Acquaviva G.; de Biase D.; Diquigiovanni C.; Argento C.M.; De Leo A.; Bonora E.; Rhoden K.J.; Pession A.; Tallini G.; BRAF exon 15 mutations in papillary carcinoma and adjacent thyroid parenchyma: A search for the early molecular events associated with tumor development. Cancers 2020,12(2),430

4. Saito H.; Takada T.; Miyazaki M.; Miyakawa S.; Tsukada K.; Nagino M.; Kondo S.; Furuse J.; Tsuyuguchi T.; Kimura F.; Yoshitomi H.; Nozawa S.; Yoshida M.; Wada K.; Amano H.; Miura F.; Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 2008,15(1),63-68

5. Yin Z.; Yang G.; Qian B.; Liang T.; Guo L.; The multiple molecular signatures in gallbladder carcinoma: From basic studies to clinical application. J Bioinform Syst Biol 2019,2(2)